Icosavax (Nasdaq:ICVX) - Stock Price, News & Analysis

ICVX Stock Overview

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. More details

ICVX fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Makes less than USD$1m in revenue ($0)

Shareholders have been diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months

Icosavax, Inc. Competitors

Vir Biotechnology

NasdaqGS:VIR

US$1.0b

AnaptysBio

NasdaqGS:ANAB

US$733.3m

REGENXBIO

NasdaqGS:RGNX

US$474.6m

MeiraGTx Holdings

NasdaqGS:MGTX

US$494.7m

Price History & Performance

Summary of all time highs, changes and price drops for Icosavax
Historical stock prices
Current Share Price	US$15.31
52 Week High	US$16.11
52 Week Low	US$4.75
Beta	1.28
11 Month Change	-0.78%
3 Month Change	50.84%
1 Year Change	68.80%
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-56.22%

Recent updates

Icosavax to pursue COVID bivalent vaccine in 2023 as biotech highlights near-term milestones

Jul 28

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Jun 22

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Mar 24

We're Hopeful That Icosavax (NASDAQ:ICVX) Will Use Its Cash Wisely

Oct 29

Shareholder Returns

	ICVX	US Biotechs	US Market
7D	-0.6%	4.0%	2.2%
1Y	68.8%	18.3%	32.6%

Return vs Industry: ICVX exceeded the US Biotechs industry which returned 4.8% over the past year.

Return vs Market: ICVX exceeded the US Market which returned 20.5% over the past year.

Price Volatility

Is ICVX's price volatile compared to industry and market?
ICVX volatility
ICVX Average Weekly Movement	15.1%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stable Share Price: ICVX's share price has been volatile over the past 3 months.

Volatility Over Time: ICVX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2017	60	Adam Simpson	icosavax.com

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target.

Icosavax, Inc. Fundamentals Summary

How do Icosavax's earnings and revenue compare to its market cap?
ICVX fundamental statistics
Market cap	US$777.79m
Earnings (TTM)	-US$96.71m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-8.0x

P/E Ratio

Is ICVX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ICVX income statement (TTM)
Revenue	US$0
Cost of Revenue	US$70.04m
Gross Profit	-US$70.04m
Other Expenses	US$26.67m
Earnings	-US$96.71m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-1.90
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did ICVX perform over the long term?

See historical performance and comparison

ICVX Stock Overview

Risk Analysis

Icosavax, Inc. Competitors

NasdaqGS:VIR

US$1.0b

NasdaqGS:ANAB

US$733.3m

NasdaqGS:RGNX

US$474.6m

NasdaqGS:MGTX

US$494.7m

Price History & Performance

Recent News & Updates

Icosavax Files Form 15

Icosavax, Inc.(NasdaqGS:ICVX) dropped from NASDAQ Composite Index

Icosavax's Shares to be Delisted from the Nasdaq Stock Market

AstraZeneca PLC (LSE:AZN) completed the acquisition of Icosavax, Inc. (NasdaqGS:ICVX) from RA Capital Management, L.P., Qiming U.S. Healthcare Fund II, L.P., managed by Qiming Weichuang Venture Capital Management (Shanghai) Company Limited and others.

President exercised options and sold US$214k worth of stock

President exercised options to buy US$1.5m worth of stock.

Recent updates

Icosavax Files Form 15

Icosavax, Inc.(NasdaqGS:ICVX) dropped from NASDAQ Composite Index

Icosavax's Shares to be Delisted from the Nasdaq Stock Market

AstraZeneca PLC (LSE:AZN) completed the acquisition of Icosavax, Inc. (NasdaqGS:ICVX) from RA Capital Management, L.P., Qiming U.S. Healthcare Fund II, L.P., managed by Qiming Weichuang Venture Capital Management (Shanghai) Company Limited and others.

President exercised options and sold US$214k worth of stock

President exercised options to buy US$1.5m worth of stock.

Chief Medical Officer notifies of intention to sell stock

Treasurer & Chief Business Officer notifies of intention to sell stock

Price target decreased by 12% to US$21.35

AstraZeneca PLC (LSE:AZN) entered into an agreement to acquire Icosavax, Inc. (NasdaqGS:ICVX) for $760 million.

AstraZeneca PLC (LSE:AZN) entered into an agreement to acquire Icosavax, Inc. (NasdaqGS:ICVX) for $760 million.

New major risk - Revenue and earnings growth

New minor risk - Share price stability

President notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

We Think Icosavax (NASDAQ:ICVX) Can Afford To Drive Business Growth

Treasurer & Chief Business Officer notifies of intention to sell stock

Price target increased by 14% to US$23.51

Icosavax, Inc. Announces Positive Topline Interim Results from Its Phase 1 Clinical Trial of Ivx-A12 Against Respiratory Syncytial Virus (Rsv) and Human Metapneumovirus (hMPV) in Older Adults

Chief Scientific Officer notifies of intention to sell stock

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 14% to US$20.69

Will Icosavax (NASDAQ:ICVX) Spend Its Cash Wisely?

President notifies of intention to sell stock

Icosavax, Inc. Appoints Jennifer Raymond as Senior Vice President, Technical Operations

President notifies of intention to sell stock

Chief Scientific Officer recently sold US$219k worth of stock

Icosavax Reports Positive Durability Data for VLP Vaccine Candidate IVX-121 Against RSV at Six-Month Timepoint

Third quarter 2022 earnings released: US$0.55 loss per share (vs US$1.30 loss in 3Q 2021)

Is Icosavax (NASDAQ:ICVX) In A Good Position To Invest In Growth?

Icosavax, Inc. Initiates Phase 1 Trial of IVX-A12 Against RSV and hMPV in Older Adults

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Icosavax GAAP EPS of -$0.57

Chief Scientific Officer notifies of intention to sell stock

Icosavax Announces Results from Ivx-411 Drug Product Investigation and Outlines Additional Corporate Milestones

Icosavax to pursue COVID bivalent vaccine in 2023 as biotech highlights near-term milestones

Icosavax, Inc. Announces Positive Topline Interim Phase 1/1b Results for VLP Vaccine Candidate IVX-121 Against RSV

Icosavax, Inc.(NasdaqGS:ICVX) dropped from Russell 2000 Growth Index

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

High number of new directors

Icosavax, Inc., Annual General Meeting, Jun 10, 2022

Independent Chair recently bought US$300k worth of stock

Consensus revenue estimates increase by 36%

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Treasurer & Chief Business Officer notifies of intention to sell stock

Insider exercised options to buy US$1.2m worth of stock.

Chief Medical Officer exercised options to buy US$897k worth of stock.

President exercised options and sold US$91k worth of stock

High number of new and inexperienced directors

We're Hopeful That Icosavax (NASDAQ:ICVX) Will Use Its Cash Wisely

Icosavax, Inc. Announces the Initiation of A Phase 1/1B Clinical Trial of IVX-121

Independent Chairman of the Board Tadataka Yamada has left the company

Independent Chairman of the Board Tadataka Yamada has left the company

Shareholder Returns

Price Volatility

About the Company

Icosavax, Inc. Fundamentals Summary

0.0x

-8.0x